Quest Diagnostics announced the launch of a new blood biomarker test for phosphorylated tau 217, or p-tau217. P-tau217 is a biomarker associated with Alzheimer’s Disease, supported by research as useful for an early diagnosis of AD. The test is the latest addition to the AD-Detect portfolio of blood tests for assessing the risk of Alzheimer’s Disease, which also includes testing for an array of AD biomarkers, including p-tau181 and amyloid beta proteins, as well as Apolipoprotein E isoform and plasma testing, for patients with cognitive impairment. The test is expected to be available for ordering on April 26.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $138 from $135 at Baird
- Quest Diagnostics and Broad Clinical Labs announce collaboration
- Ex-Dividend Date Nearing for These 10 Stocks – Week of April 1, 2024
- Quest Diagnostics management to meet with UBS
- Moderna downgraded, Gap upgraded: Wall Street’s top analyst calls
